tradingkey.logo

Health Catalyst Inc <HCAT.OQ> expected to post breakeven results a share - Earnings Preview

ReutersMay 5, 2025 11:01 PM
  • Health Catalyst Inc HCAT.OQ HCAT.O is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025

  • The South Jordan Utah-based company is expected to report a 5.9% increase in revenue to $79.169 million from $74.72 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.The company's guidance on February 26 2025, for the period ended March 31, was for revenue of $79.000 million.

  • ​LSEG's mean analyst estimate for Health Catalyst Inc is for breakeven results per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 1.1% in the last three months. ​

  • Wall Street's median 12-month price target for Health Catalyst Inc is $7.25​, above​ its last closing price of $4.07. ​​​

The company's guidance on February 26 2025 for the period ended March 31 was for Earnings before Interest, Taxes, Depreciation and Amortization of of USD4 million.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

0.07

0.07

0.04

Missed

-45.9

Sep. 30 2024

0.10

0.10

0.07

Missed

-28.3

Jun. 30 2024

0.09

0.08

0.12

Beat

51.3​

Mar. 31 2024

0.03

0.03

0.05

Beat

79

​​Dec. 31 2023

0.01

0.00

0.02

Beat

2,700

Sep. 30 2023

0.00

-0.02

0.03

Beat

275.6​

Jun. 30 2023

-0.01

0.00

0.05

Beat

1,447.7

Mar. 31 2023

-0.04

-0.04

0.05

Beat

222.9

This summary was machine generated May 5 at 23:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI